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Abstract
Purpose: Radiation therapy dose escalation using stereotactic body radiation therapy may signiﬁcantly improve both local control
(LC) and overall survival (OS) for patients with inoperable pancreas cancer. However, ablative dose cannot be routinely offered
because of the risk of causing severe injury to adjacent normal organs. Stereotactic magnetic resonance (MR)-guided adaptive
radiation therapy (SMART) represents a novel technique that may achieve safe delivery of ablative dose and improve long-term
outcomes.
Methods and Materials: We performed a single institution retrospective analysis of 35 consecutive pancreatic cancer patients treated
with SMART in mid-inspiration breath hold on an MR-linear accelerator. Most had locally advanced disease (80%) and received
induction chemotherapy (91.4%) for a median 3.9 months before stereotactic body radiation therapy. All were prescribed 5 fractions
delivered in consecutive days to a median total dose of 50 Gy (BED10 100 Gy10), typically with a 120% to 130% hotspot. Elective nodal
irradiation was delivered to 20 (57.1%) patients. No patient had ﬁducial markers placed and all were treated with continuous
intrafraction MR visualization and automatic beam triggering.
Results: With median follow-up of 10.3 months from SMART, acute (2.9%) and late (2.9%) grade 3 toxicities were uncommon. Oneyear LC, distant metastasis-free survival, progression-free survival, cause-speciﬁc survival, and OS were 87.8%, 63.1%, 52.4%, 77.6%,
and 58.9%, respectively.
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the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Conclusions: To our knowledge, this is the ﬁrst report of 5-fraction pancreas SMART delivered on an MR-linear accelerator. We
observed minimal severe treatment-related toxicity and encouraging early LC. Prospective conﬁrmation of feasibility and long-term
clinical outcomes of dose intensiﬁed SMART is warranted.
Ó 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction
Pancreas cancer has a dismal prognosis with 5-year
overall survival (OS) of <5% despite aggressive management.1 Although the effect of nonablative radiation
therapy (RT) on OS for locally advanced pancreas cancer
(LAPC) continues to be debated, randomized data
demonstrate improved local control (LC) with chemoradiation versus chemotherapy alone.2 This is meaningful
as up to one-third of patients may die of local progression
rather than distant metastases.3
A growing body of literature suggests that escalation
of the biologically effective dose (BED) may improve LC,
which may improve OS for inoperable patients.4e10
Furthermore, published guidelines recommend that dose
escalation be considered if appropriate resources, such as
motion management and daily image guidance are
available to ensure safety.11 However, delivery of ablative
dose (eg, [BED10] 100 Gy10) to the majority of gross
disease using computerized tomography (CT) guidance is
not attempted for most patients owing to the proximity of
tumor to luminal gastrointestinal (GI) organs at risk
(OAR).12
Magnetic resonanceeguided radiation therapy
(MRgRT) represents a novel solution to deliver ablative
dose to larger volumes of gross disease regardless of
proximity to OARs in up to 5 fractions owing to several
key features: (1) superior soft tissue visualization
compared with CT,13 (2) real-time continuous intrafraction assessment of internal structures, (3) automatic
beam gating based on target position, and (4) daily ontable adaptive replanning.14e16 A multi-institutional
retrospective analysis of stereotactic MR-guided adaptive radiation therapy (SMART) using cobalt-60 (Co-60)
demonstrated encouraging survival with no high-grade
toxicity among patients who received dose escalation.5
These outcomes are supported by a recent single institution report of 5-fraction SMART, mostly delivered using
Co-60.17
The ﬁrst MR-linear accelerator (LINAC) became clinically operational in 2017, offering improved dosimetry
with multiﬁeld intensity modulated radiation therapy
(IMRT) compared with Co-60 and achieving comparable
plan quality to a conventional c-arm linac.18,19 Higher dose
conformality made feasible by the MR-LINAC increases
the potential for higher target doses previously not achieved
with the ﬁrst-generation MRgRT Co-60 machines.

To the best of our knowledge, we report the ﬁrst
clinical experience of 5-fraction SMART for initially
inoperable pancreas cancer exclusively on an MRLINAC.

Methods and Materials
Patient details and clinical evaluation
After obtaining institutional review board approval, a
retrospective analysis was performed of 35 consecutive
nonmetastatic patients with biopsy-proven pancreas
adenocarcinoma who were treated with SMART on the
ViewRay MRIdian Linac (Oakwood Village, OH) between October 2018 and November 2019 at a single
institution.
No minimum distance between tumor and GI luminal
organs was required for patients to be considered for
SMART. Duodenal invasion based on endoscopic evaluation was a contraindication. Patients were offered
SMART regardless of tumor size or number of involved
regional lymph nodes. No patient had previously received
abdominal RT.
All underwent endoscopic ultrasound and CT scans of
the chest, abdomen, and pelvis for initial staging. The
majority also had either diagnostic MRI abdomen or
positron emission tomography scans. Staging and resectability was determined according to the National
Comprehensive Cancer Network guidelines.20
Nearly all (91.4%) received induction chemotherapy
for a median 3.9 months (range, 2-12.3 months) before
SMART, most commonly with FOLFIRINOX (5ﬂuorouracil, irinotecan, leucovorin, oxaliplatin; 60%)
and otherwise gemcitabine-based regimens. Three patients did not receive induction chemotherapy because of
suboptimal performance status. No patient received concurrent chemotherapy.

RT treatment planning and delivery
Simulation was performed without delay for ﬁducial
marker placement because MR guidance provides direct
visualization of the tumor obviating the need for a surrogate marker. Patient geometry was supine and typically
with both arms down at sides to improve patient comfort
and beam angles were avoided that would treat through
the arms.18 Simulation included a planning 0.35 T mid-
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inspiration breath hold, balanced steady-state free precession sequence (TrueFISP) MR scan (17-25 sec) acquired on the MRIdian Linac immediately followed by a
planning CT scan. No immobilization device was used
because daily 3-dimensional and 2-dimensional MRI was
performed for inter and -intrafraction motion management, respectively.
The target and OAR contours were delineated on the
TrueFISP MR simulation scan and exported to the
MRIdian treatment planning system. The simulation CT
was also exported to MRIdian treatment planning system
and deformably registered to the simulation MR scan for
electron density information for dose calculation purposes. For some cases, bulk density assignment to the
vertebral bodies as bone, external as water, and any
abdominal gas as air was used to account for changes in
anatomy between simulation CT and MRI. Intravenous or
oral contrast was not given because the tumor and normal
anatomy were well-visualized on the MR simulation scan
and diagnostic imaging was fused as needed to deﬁne the
target volumes.
The MRIdian Linac uses a step-and-shoot IMRT
treatment delivery as has been previously described.21,22
Table 1 lists the OAR constraints used for initial planning and on-table adaptive replanning. A 12 to 18 beam,
step-and-shoot IMRT plan was created with a 2.0 mm3
resolution Monte Carlo dose calculation and magnetic
ﬁeld corrections. All plans underwent a measurementbased veriﬁcation quality assurance using criteria of 2%/
2 mm distance-to-agreement for a g-analysis pass rate of
90%.
Gross target volume (GTV) was deﬁned as gross tumor
within the pancreas and involved locoregional lymph
nodes as seen on diagnostic imaging and simulation CT or
MR scans; this was uniformly expanded by 3 mm to
create the planning target volume (PTV). A 3 to 5 mm
expansion of the GI OARs was performed to create
planning organ at risk volumes (PRVs). Any overlapping
portion of the GTV or PTV by the PRVs was strictly
constrained to 35 Gy to facilitate meeting OAR constraints and the remainder was dose-escalated to 50 Gy
(n Z 30; 85.7%) although several patients in our early

Table 1 Organ at risk constraints for 5-fraction pancreas
stereotactic magnetic resonance image guided adaptive radiation therapy
Organ at risk

Dose constraint

Stomach, duodenum, small bowel

V35 <0.5 mL
V40 <0.03 mL
V38 <0.5 mL
V43 <0.03 mL
Mean <10 Gy
Mean <15 Gy
V25 <0.03 mL

Large bowel
Kidneys
Liver
Spinal cord

experience were prescribed 40 Gy (n Z 1; 2.9%) or 45
Gy (n Z 4; 11.4%) owing to initial uncertainty about
patient tolerability. Grossly involved lymph nodes were
prescribed the same dose as the primary tumor. The
dosimetric hotspot was optimized to be 120% to 130%
of the prescription dose and encompassed as much of the
PTV outside of the PRV as possible provided that OAR
constraints were met.
Real-time tissue tracking on sagittal image acquisition
every 250 ms was performed to automatically gate the
treatment delivery.23 The tracking region of interest was
deﬁned daily from the GTV. Beam delivery was automatically paused when >3% to 5% of the tracking region
of interest was displaced by >3 mm from its prescribed
location. Treatment was delivered for all patients in midinspiration breath hold to optimize duty cycle
efﬁciency.24
Our initial practice was to treat gross disease only and
not elective nodal regions. After it was apparent that
treatment was tolerated well we eventually adopted the
routine use of elective nodal irradiation (ENI); this decision was inﬂuenced by patterns of failure data indicate
that ENI may reduce locoregional failures.6,25 As such,
ENI was delivered to the more recently treated 20 patients
(57.1%) and the electively treated region gradually
evolved to include a 5 to 10 mm radial expansion around
the celiac axis, superior mesenteric vein, and superior
mesenteric artery; up to the proximal 10 to 15 mm of
these vessels was also included. Instead of routinely
creating a clinical target volume, electively treated regions
were typically included within the GTV to minimize the
number of structures, expedite daily adaptive replanning,
and reduce time patients were in the treatment unit. As
such, electively treated regions were usually prescribed
the same dose as gross disease.

On-table adaptive workﬂow
Our on-table adaptive MRgRT workﬂow was based on
prior publications.15,26 Target volumes were rigidly
registered from the simulation MR to the daily volumetric
MR scan frame of reference and OARs underwent
deformable registration. The target volumes were not
modiﬁed because a change in gross tumor was not expected over the course of 5 fractions. OAR contours
within 3 cm radially of the PTV and 2 cm cranial or
caudal of the PTV were edited to reﬂect the anatomy of
the day (Fig. 1).15 The optimization target volume
assigned to the ablative prescription dose was updated to
exclude the GI PRVs of the day.
After recontouring structures based on the current
day’s MRI anatomy, calculation of the initial plan using
the current day’s contours was performed to understand
the predicted dose to targets and OARs. A predicted plan
was created for all 175 fractions because visual
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Figure 1 Target volumes (top row) and isodose lines (bottom row) for a pancreas cancer patient prescribed 50 Gy in 5 consecutive
fractions with daily magnetic resonance image guidance and on-table adaptive replanning. Abbreviations: OAR organs at risk; PTV Z
planning target volume.

assessment of the daily images alone has been shown to
not be adequate for decision making about the indication
for adaptation.26 Plan reoptimization was performed to
meet dose constraints or improve target coverage; priority
was always to ensure that OAR constraints were met even
at the expense of target coverage. If all constraints were
met on the predicted dose and the target coverage was not
improved for the reoptimized plan, then the predicted plan
was used. Plan prediction and reoptimization did not account for prior dose delivered. Before treatment, plan ﬁdelity was veriﬁed through a secondary Monte Carlo
quality assurance dose calculation.

Follow-up and outcomes assessment
Patients were followed with CT or MRI scans and
CA19-9 assessment starting 4 to 6 weeks after SMART
and every 2 to 3 months thereafter, or sooner as clinically
indicated. No patient was prescribed a proton pump inhibitor after SMART. Chemotherapy was typically not
started after SMART unless there was evidence of disease
progression.
Toxicity was deﬁned according to the Common Terminology Criteria for Adverse Events (CTCAE version

5.0). We evaluated the highest grade toxicity experienced
by each patient, with acute toxicity being considered to
have occurred during or within 90 days after the start of
SMART. All toxicity was prospectively evaluated upon
each clinic encounter and recorded in the patient’s electronic medical record.

Statistical analysis
Study data were collected and managed using
Research Electronic Data Capture27 and statistical analyses were performed using SAS (version 9.4, SAS
Institute, Cary, NC). Wilcoxon rank-sum test was used to
compare time from initial setup to treatment delivery
completion, time to deliver treatment, and in-room time
between initial and more recently treated patients. Followup time was determined from the ﬁrst day of SMART
until the date of last patient contact or death. All clinical
outcomes were assessed from the date of SMART initiation and were determined using the Kaplan-Meier
method. LC was deﬁned as lack of progression of the
primary pancreas tumor or within regional lymph nodes
according to Response Evaluation Criteria in Solid Tumors 1.1 criteria, distant metastasis-free survival was
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deﬁned as time to distant recurrence, and progression-free
survival (PFS) was deﬁned as the time from ﬁrst delivered
SMART fraction to local recurrence, distant recurrence,
or death. Cause-speciﬁc survival (CSS) was deﬁned as the
time to death owing to pancreas cancer whereas OS was
deﬁned as the time to death from any cause.

Results
Table 2 describes patient and tumor characteristics. A
total of 35 consecutive patients were evaluated with median age of 67 years (range, 34-89 years), most frequently
with tumors in the head of pancreas (88.6%) and with
locally advanced disease (80%). Median CA19-9 at initial
diagnosis was 102.5 U/mL (range, 0.9-1517.5 U/mL) and
this decreased to a median of 47.0 U/mL (range, 1.2216.6 U/mL) at a median 5 weeks before SMART.
The median follow-up for all patients was 10.3 months
(range, 2.2-17.9) and 12.5 months for 21 patients (60%)
who were alive at time of analysis (range, 4.5-14.2). All
patients had at least 3 months of follow-up except for one
who died 2.2 months after SMART; 15 patients (42.9%)
were followed for at least 12 months from SMART.

Treatment planning and delivery
The median GTV and PTV for all patients were 65.6
mL and 99.8 mL, respectively. The median GTV and
PTV of patients who did not receive ENI were 28.44 mL
(range, 6.1-66.9 mL) and 43.2 mL (range, 11.3-68.6 mL),
respectively, and for patients treated with ENI, they were
102.0 cc (range, 55.1-284.3 mL) and 141.0 mL (range,
77.1-368.1 mL), respectively.
The median number of fractions that met criteria for
adaptive replanning was 5 (range, 1-5). Across all fractions, 169 (96.6%) were adapted online and all 5 fractions
were adapted online for 33 patients (94.3%).
Table 3 displays the target volume coverage in total
dose for the initial plan on the simulation anatomy versus
on-table adaptive plans on the daily anatomy. Ablative
dose was delivered to most of the target volumes on the
initial plans as demonstrated by the median GTV and
PTV D80 (52.5 Gy, 46.2 Gy) and D90 (50.8 Gy, 39.8 Gy),
respectively. Furthermore, the prescribed dose covered a
median 80.5% of the PTV on the initial plans. Despite the
need to adapt most fractions we were able to maintain
excellent high dose coverage (median D80: 49.6 Gy, 44.7
Gy and median D90: 47.5 Gy, 40.5 Gy) to most of the
GTV and PTV, respectively. The prescription dose
covered a median 70.4% of the PTV across all delivered
fractions. Figure 2 illustrates differences in GTV and PTV
coverage across 5 adapted fractions due to interfraction GI
OAR changes for a patient prescribed 50 Gy.
The median time from initial setup to treatment delivery completion was 83 minutes (range, 56-108
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Patient, tumor, and treatment characteristics

Characteristic

N (range)

Total no. of patients
35
Age (y), median
67 (34-89)
Sex
Male
21 (60%)
Female
14 (40%)
Tumor location
Head
31 (88.6%)
Body/tail
4 (11.4%)
ECOG performance status
0
20 (57.1%)
1
12 (34.3%)
2
3 (8.6%)
Initial staging scans
CT alone
8 (22.9%)
CT and MRI
14 (40%)
CT and PET
4 (11.4%)
CT, MRI, and PET
9 (25.7%)
Stage
Locally advanced
28 (80%)
Borderline resectable
3 (8.6%)
Medically inoperable
4 (11.4%)
Clinical T stage
1
0
2
7 (20%)
3
2 (5.7%)
4
26 (74.3%)
Clinical N stage
0
25 (71.4%)
1
9 (25.7%)
2
1 (2.9%)
Clinical M stage
0
35 (100%)
1
0
CA 19-9 (U/mL), median
Initial diagnosis
102.5 (0.9-1517.5)
Before SMART
47 (1.2-216.6)
Induction chemotherapy
FOLFIRINOX
18 (51.4%)
gemcitabine/nab-paclitaxel
7 (20%)
FOLFIRINOX then gemcitabine/
3 (8.6%)
Nab-paclitaxel
gemcitabine alone
4 (11.4%)
none
3 (8.6%)
Induction chemotherapy duration (mo),
3.9 (2-12.4)
median
Radiation dose
Total prescribed dose (Gy), median
50 (40-50)
Total prescribed fractions
5
Motion management
Breath hold
30 (85.7%)
Free breathing gating
5 (14.3%)
Elective nodal irradiation
Yes
20 (57.1%)
No
15 (42.9%)
On-table plan adaptation
Adapted fractions per patient, median
5 (1-5)
(continued on next page)
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evidence of disease progression. Thirteen received
chemotherapy owing to disease progression and 5
received maintenance chemotherapy owing to medical
oncologist preference.
Three patients received irreversible electroporation
(IRE) at a median 11 months (7.3-11.1 months) after
SMART. IRE was used to manage regional progression
outside of the PTV in 2 patients; neither had distant
metastasis. A third patient with stable disease had IRE
despite lack of tumor progression, with intraoperative
biopsy before IRE being negative for invasive
adenocarcinoma.
Five patients underwent a Whipple procedure performed at a median 2 months (range, 1-9 months) after
completing SMART, 3 with borderline resectable and 2
with locally advanced tumors. All resected patients
received induction FOLFIRINOX (n Z 4) or
gemcitabine/nab-paclitaxel (n Z 1). The prescribed radiation dose was 50 Gy (n Z 4) or 40 Gy (n Z 1). Four
patients had negative margins and 4 had negative lymph
nodes. One had a complete response, 2 had a near complete pathologic response, and 2 were noted to have a
marked pathologic response. None of these patients has
evidence of tumor recurrence after median 10.8 months
follow-up.

Table 2 (continued )
Characteristic

N (range)

Therapy after SMART
Irreversible electroporation
Pancreaticoduodenectomy
Chemotherapy
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3 (8.6%)
5 (14.3%)
18 (51.4%)

Abbreviations: CA Z cancer antigen; CT Z computed tomography;
ECOG Z Eastern Cooperative Oncology Group; FOLFIRINOX Z
5-ﬂuorouracil, irinotecan, leucovorin, oxaliplatin; MRI Z magnetic
resonance imaging; PET Z positron emission tomography; SMART
Z stereotactic magnetic resonance image guided adaptive radiation
therapy.

minutes) for all patients. Although not statistically signiﬁcant, this was longer for the initial 17 patients
compared with the more recent 18 patients (86 vs 79.5
minutes; P Z .141) possibly reﬂecting our improved
proﬁciency with the MR-LINAC over time, which had
been operational in our department for only 6 months
when we treated the ﬁrst patient in this study. Treatment
was delivered over a median 20 minutes (range, 11-36
minutes) for all patients and was similar for the initial 17
patients compared with the more recent 18 patients (20 vs
18 minutes; P Z .235) despite the transition to ENI that
resulted in large target volumes.
We recently installed a monitor in the treatment room
to show patients their real-time sagittal cine MR images
and required breath hold position throughout each fraction.28 The intent was to provide visual biofeedback as a
means to decrease the number of breath holds and treatment times compared with only audio coaching through
headphones, which was used for the initial 28 patients.
The median in-room time for the 9 patients treated with
versus without the monitor was 67 versus 85 minutes
(P Z .032).

Tumor control and survival
Three patients had local progression although only 1
occurred within the PTV (45 Gy prescription without ENI).
The other 2 patients (50 Gy prescription with ENI for both)
progressed regionally outside of the PTV, one within a
lymph node and another along the SMA abutting the PTV.
The 1-year LC was 87.8% (95% conﬁdence interval [CI],
79.4%-93.8%) and the median time to local progression
was 7.4 months (range, 2.5-9.8 months; Fig. 3a). Thirteen
patients developed distant metastasis after a median 3.0
months (range, 1.0-11.8 months). The 1-year distant
metastasis-free survival was 63.1% (95% CI, 55.7%69.5%; Fig. 3b). The 1-year PFS and median PFS were
52.4% (95% CI, 45.1%-58.2%) and 7.9 months,

Therapy after SMART
Approximately half of patients did not resume
chemotherapy after SMART (48.6%), most without

Table 3 Target volume coverage reported in total dose for initial plan on simulation anatomy versus on-table adaptive plans on
daily anatomy
Target volume

Initial plan on simulation anatomy (total dose)
median

PTV D90
GTV D90
PTV D80
GTV D80
PTV Max
GTV Max
PTV Mean
GTV Mean

39.8
50.8
46.2
52.5
65.9
65.4
52.7
56.3

Gy
Gy
Gy
Gy
Gy
Gy
Gy
Gy

mean  SD
43.9
50.4
45.9
51.9
65.2
61.8
52.0
60.3










6.3
6.2
5.6
4.7
5.7
4.9
3.9
3.4

Gy
Gy
Gy
Gy
Gy
Gy
Gy
Gy

Adaptive plan on daily anatomy (total dose)

range
32.7-53.0
38.8-58.3
37.4-54.9
44.1-58.8
49.9-74.1
57.8-73.1
42.7-58.3
49.4-60.1

median
Gy
Gy
Gy
Gy
Gy
Gy
Gy
Gy

40.5
47.5
44.7
49.6
65.7
65.4
50.5
54.4

Gy
Gy
Gy
Gy
Gy
Gy
Gy
Gy

mean  SD
40.9
47.2
44.7
50.1
64.9
64.9
50.4
54.0










6.0
5.8
5.4
4.7
6.1
6.0
4.7
4.0

Gy
Gy
Gy
Gy
Gy
Gy
Gy
Gy

range
26.8-68.1
32.1-68.1
25.6-63.3
39.4-69.2
59.8-76.1
59.8-76.1
43.8-67.6
46.9-70.8

Gy
Gy
Gy
Gy
Gy
Gy
Gy
Gy

Abbreviations: D90 Z dose to 90% of volume; GTV Z planning target volume; PTV Z planning target volume; D80 Z dose to 80% of volume; SD
Z standard deviation.
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Figure 2 Dose-volume histograms for a patient prescribed 50 Gy that illustrates differences across 5 adapted fractions in coverage of
the (a) gross target volume and (b) planning target volume.

respectively (Fig. 3c). Of the 13 patient deaths, 6 were not
related to pancreas cancer: cardiac arrest (n Z 2), sepsis (n
Z 2), head trauma related to a fall (n Z 1), and pneumonia
(n Z 1). The 1-year OS and median OS were 58.9% (95%
CI, 51.6%-65.1%) and 9.8 months, respectively (Fig. 3d).
The 1-year CSS and median CSS were 77.6% (95% CI,
72.7%-84.8%) and 9.8 months, respectively (Fig. 3e).

transfusion. Late grade 3 toxicity (bile duct stenosis)
occurred in 1 patient (2.9%) without evidence of disease
progression that required percutaneous drainage. No
grade 4 to 5 events were observed.

Toxicity

The proximity of OARs creates a formidable challenge
in achieving signiﬁcant tumor dose intensiﬁcation to
inoperable pancreas cancers and sparing especially the
stomach and bowel, as to not cause serious harm to the
patient. The importance of limiting high dose to GI
luminal organs was illustrated by the early pancreas

Acute grade 2 toxicity (nausea, anorexia) occurred in 3
patients (8.6%). Acute grade 3 toxicity (diarrhea) was
reported in 1 patient (2.9%). One patient (2.9%) had late
grade 2 duodenal bleeding that did not require

Discussion

Practical Radiation Oncology: March-April 2021
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Figure 3 Kaplan-Meier plots for (a) local control, (b) distant metastasis-free survival, (c) progression-free survival, (d) overall survival, and (e) cause-speciﬁc survival.

stereotactic body radiation therapy (SBRT) experiences
that reported signiﬁcant toxicities.29e31 For example, a
Dutch phase II trial of 45 Gy in 3 fractions (BED10 Z
112.510) that used PTV margins up to 10 mm and without
high-quality on-board CT imaging reported that 94% of
patients had at least grade 2 pain at 3 months after
treatment and multiple patients developed severe GI ulceration or perforation likely because at least 67% of the
prescribed dose was delivered to the stomach or

duodenum.30 Consequently, prioritization of OAR constraints over target volume coverage is strongly
recommended.32
The outcomes of SBRT to 24 to 36 Gy in 3 to 5
fractions (BED10 Z 37.5-79.2 Gy10) have been modest,
although both LC and OS worsen with longer follow-up
beyond at least 1 year.33e37 For example, a phase II
trial by Quan et al of sequential gemcitabine/capecitabine
and 36 Gy in 3 fractions (BED10 79.2 Gy10) reported
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Figure 3

1-year LC and OS of 78% and 54% although 2-year LC
and OS decreased to 52% and 10%, respectively, among
nonsurgical patients.
There has recently become greater enthusiasm in radiation dose escalation for inoperable pancreas cancer to
potentially improve clinical outcomes.4e8,10,17 Investigators from MD Anderson Cancer Center reported
that LAPC patients, typically treated in 28 fractions with

(continued.)

daily CT guidance, had higher median survival (17.8 vs
15.0 months; P Z .03) and local-regional relapse free
survival (10.2 vs 6.2 months; P Z .05) when a biologically effective dose (BED10) >70 Gy10 was prescribed
(Table 4).4 Dose intensiﬁcation was considered, typically
with fractionation over multiple weeks to mitigate
toxicity, if there was 1 cm between tumor and luminal
GI structures. This is uncommon and highlights the need
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for technologies that can safely achieve dose escalation
for a broader population.
MRgRT is a novel technique that facilitates dose
escalation in the abdomen beyond what has been historically feasible using CT.5,17,22,38 SMART delivered with
Co-60 was tolerated remarkably well in an analysis by
Rudra et al of 44 pancreas patients, with 25 receiving dose
escalation to 40 to 67.5 Gy over 5 to 15 fractions.5 The
minority received 5 fractions although it was not speciﬁed
how many received at least 50 Gy (BED10 100 Gy10); it
was likely a small number given the median prescribed
BED10 was 77.6 Gy10. Similar to the MD Anderson
Cancer Center analysis, BED10 >70 Gy10 was associated
with improved outcomes. Earlier this year, a retrospective
analysis of SMART prescribed to 50 Gy in 5 fractions
without ENI was published by investigators at Washington University in St. Louis that included 44 inoperable
pancreas cancer patients, most (86%) treated on a Co-60
system.17 With median follow-up of 16 months from
pancreas cancer diagnosis, outcomes included 2-year LC,
PFS, and OS of 59.3%, 13.9%, and 37.9%, respectively.
Treatment was very well tolerated with limited grade 3
toxicity.
To the best of our knowledge the present study represents the ﬁrst reported outcomes of ablative 5-fraction
pancreas SMART delivered only on an MR-LINAC. With
median follow-up of 10.3 months from SMART our early
outcomes are encouraging. Although we cannot draw
conclusions about the effect of ENI on our 1-year LC of
87.8%, which is encouraging compared with other studies,4,34e37 it is notable that only 1 patient had disease
progression within the PTV, and the others progressed
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regionally outside of the PTV. Furthermore, the use of
ENI was not associated with signiﬁcant toxicity.
Although our 1-year OS of 58.9% is similar to other
pancreas SBRT studies that prescribed nonablative doses,
nearly half of deaths were not related to pancreas cancer
or to treatment-related toxicity. Lastly, grade 3 toxicity
occurred in only 2 patients, which likely was achieved by
interfraction anatomic changes being visualized daily on
MRI and on-table adaptive replanning being able to account for these changes.
There are several aspects of our treatment approach
worth emphasizing. First, there was no need to refer patients for ﬁducial marker placement, which could otherwise delay simulation up to several weeks. There was
only a median 1 day between consultation to simulation
and a median 13 days from consultation to delivery of
ﬁrst fraction for patients in our study. Whether decreasing
the interval to start of RT effects long-term outcomes
remains unknown; in the short-term this can mitigate
patient anxiety especially because some patients are
referred for RT with local progression while on chemotherapy. Second, treatment was delivered in consecutive
days and we did not prescribe a prophylactic proton pump
inhibitor. Third, continuous intrafraction tissue tracking
permitted breath hold delivery, eliminating the need for an
internal target volume and thereby reducing the volume of
normal tissue exposed to high dose. Direct intrafraction
visualization of the tumor and in-plane OARs abutting the
high dose gradient enabled not only greater conﬁdence
throughout the ablative dose delivery, but also allowed for
treatment halting and repeat 3-dimensional MRI to adjust
for the intrafraction motion detected on 2-dimensional
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Table 4

Selected studies of radiation therapy for patients with inoperable pancreas adenocarcinoma
Image
Resectability N
guidance

BED10
Total
(Gy10)
dose
and no.
fx

ENI
used

Median
PTV
volume

Surgery
after RT

Median
FU (mo)

LC

OS

Acute grade
3þ toxicity

Hoyer
et al30

x-ray

Portal
100% LA
imaging

22

45 Gy 112.4
in 3 fx

No

0%

NR

6-mo: 57%

1-y: 5%

Grade 2þ:
79%

Herman
et al36

x-ray

CBCT

100% LA

49

33 Gy i 54.8
n 5 fx

No

1-y: 78%
2-y: NR

1-y; 59%
2-y: 18%

Grade 2þ:
11%

Krishnan
et al4

x-ray

CBCT,
100% LA
CT-onrails

14
11
7
1
1
13

2 (4.3%) 9.6
1-y: 21%
(from RT) 2-y: 17%

1-y: 60%
2-y: 22%

2.0%
(diarrhea)

Quan
et al37

x-ray

CBCT

54.3% BR
45.7% LA

35

63 Gy
in 28
fx
70 Gy
in 28
fx
67.5 Gy
in 15
fx
60 Gy
in 10
fx
50 Gy
in 5 fx
51.3-70.
4 Gy in
13-39
fx
36 Gy
in 3 fx

GTV:
32 cc
(7-102
cc)
71.4
(31.9225.2 cc)
NR

Rudra
et al5

Cobalt-60

0.35T
MRI

75% LA
16.7% BR

16
9

77.2
87.5
97.9
96.0
100.0
70.4-84.3

No

79.2

No

18.9 mL
(5.5-65.2
mL)

Yes (%
NR)

73.3 mL
(13.8239.0)

median
40-52
77.6
Gy
in 5 fx median
82.7
50-67.5
Gy in
10-15
fx

4 (8.2%) 13.9
(from dx)

1-y: 54%
1-y: 78%
12
15.4
2-y: 10%
(34.3%) (from trial 2-y: 52%
(nonsurgical
enrollment) (LA only)
LA only)
2 (8.3%) 17 (from
2-y: 77%
2-y: 49%
RT)
(BED10
(BED10 >70)
>70)

0%

0% (BED10
>70)
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RT
modality
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Study

Abbreviations: 0.35T Z 0.35 Tesla; BED Z biologically effective dose; BED10 Z biologically effective dose10; BR Z borderline resectable; CBCT Z cone beam computed tomography; Dx Z diagnosis;
ENI Z elective nodal irradiation; FU Z follow-up; Fx Z fraction; LA Z locally advanced; LRC Z locoregional control; MRI Z magnetic resonance imaging; N Z number of patients; NR Z not reported;
OS Z overall survival; PTV Z planning target volume; RT Z radiation therapy.

2.9%
(diarrhea)
1-y: 58.9%
5 (14.3%) 10.3 (from
RT)
Yes
99.8 mL
(57.1%) (11.3-368.1
mL)
50 Gy 100.0
in 5 fx 85.5
45 Gy 72.0
in 5 fx
40 Gy
in 5 fx
80% LA
8.6% BR
0.35T
MRI

30
4
1

64% LA
14% BR

Hassanzadeh Cobalt-60
et al17
(86%)
x-ray
(14%)
Present
x-ray
study

0.35T
MRI

44

109 mL
(25-419
mL)
No
50 Gy 100.0
in 5 fx

1-y: 87.8%

1-y: 68.2%
2-y: 37.9%
3 (6.8%) 16 (from dx) 1-y: 84.3%
2-y: 59.3%

0%
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MRI. The need for intrafraction dose assessment and
reoptimization is currently unclear and this should be
explored in future studies.28 Fourth, we found that both
tumor and normal anatomy are visualized well on the MR
simulation and daily treatment breath hold scans without
contrast. This has improved patient satisfaction by
avoiding diarrhea, the need to check renal function, and
obtain intravenous access. We have also been able to free
up nursing resources and decrease the time needed on the
CT simulator for these patients. Fifth, most patients were
treated to elective nodal regions, which is unconventional
and frankly controversial.6,9,25 The role of ENI remains
debated and owing to potentially severe toxicity, at least
using CT image guidance, some have recommended
against it.11 Electively treated regions typically received
an ablative dose prescription, and although this was
tolerated well the long-term effects of this need to be
closely evaluated. Lastly, ablative dose covered most of
the targets as demonstrated by the median GTV and PTV
D80 and D90 on the initial plans. Despite the need to adapt
most fractions we were able to maintain ablative dose to
most of the GTV and PTV, respectively. This is in distinct
contrast to the strategy commonly used for low dose
SBRT using daily CT guidance in which dose escalation
is conﬁned to a restricted volume, for example only the
tumor-vessel interface.9,35,39,40
Study limitations include that this is a retrospective
analysis and subject to underreporting of toxicities
although toxicities were evaluated prospectively at the
time of each patient encounter. Patient numbers are small,
although are similar to most published prospective or
retrospective pancreas SBRT studies. Our results would
beneﬁt from more extended follow-up to better understand late toxicity and long-term clinical outcomes. Still,
we believe that our median follow-up of 10.3 months is
long enough to provide meaningful comparison to other
studies, especially given that the median survival for
LAPC patients is approximately 12 to 16 months.4 In
addition, whereas other analyses with longer follow-up
measured outcomes from the time of diagnosis,17,36
which then is routinely followed by at least several
months of chemotherapy, our analysis began from the
initiation of SMART. Lastly, although most fractions
were adapted the cumulative dose was not assessed with
respect to clinical outcomes.

Conclusions
In conclusion, 50 Gy in 5 consecutive fractions
delivered using an MR-LINAC to inoperable pancreas
cancer and elective nodal regions with daily on-table
adaptive replanning can achieve excellent early LC and
with limited severe toxicity. Our experience supports
enrollment to an ongoing phase II trial of 5-fraction
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ablative SMART prescribed to 50 Gy in 5 fractions
(NCT03621644).
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